Arrowhead Pharmaceuticals

2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Motley Fool
Arrowhead Pharmaceuticals
Seres Therapeutics
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
FDA grants fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 to reduce triglycerides
FDA grants fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 to reduce triglycerides
Pharmaceutical Business Review
Arrowhead Pharmaceuticals
ARO-APOC3
triglycerides
familial chylomicronemia syndrome
fast track
FDA
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Spotlight – Cystic fibrosis developers take a deep breath
Spotlight – Cystic fibrosis developers take a deep breath
EP Vantage
cystic fibrosis
MRNA
Vertex Pharmaceuticals
4D Molecular Therapeutics
Arcturus Therapeutics
Arrowhead Pharmaceuticals
Boehringer Ingelheim
Eloxx Pharmaceuticals
Krystal Biotech
Moderna Therapeutics
Oxford BioMedica
ReCode Therapeutics
SpliSense
Sumitomo Pharmaceuticals
Tessera Therapeutics
Flag link:
Janssen Returns Phase I NASH Candidate to Arrowhead
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Flag link:
JPM Day 1: Highlights
JPM Day 1: Highlights
BioSpace
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
MedCity News
Amgen
Arrowhead Pharmaceuticals
olpasiran
heart disease
Flag link:
Biotech’s near-term key catalysts
Biotech’s near-term key catalysts
EP Vantage
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Flag link:
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference
BioSpace
EASL
liver disease
Ascletis
Takeda
Arrowhead Pharmaceuticals
Flag link:
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Fierce Biotech
GSK
Arrowhead Pharmaceuticals
NASH
RNAi
Flag link:
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Endpoints
Arrowhead Pharmaceuticals
RNAi
animal research
cystic fibrosis
Flag link:
Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med
Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med
Endpoints
Horizon Therapeutics
gout
Krystexxa
Arrowhead Pharmaceuticals
ARO-XDH
Flag link:
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Endpoints
Takeda
RNAi
Arrowhead Pharmaceuticals
Rare Diseases
Flag link:
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Xconomy
Arrowhead Pharmaceuticals
clinical trials
liver disease
RNAi
ARO-AAT
Flag link:
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
BioPharma Dive
Arrowhead Pharmaceuticals
JNJ
clinical trials
RNAi
hepatitis B
Flag link:
Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?
Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?
Motley Fool
JNJ
Arrowhead Pharmaceuticals
M&A
Flag link:
Is Arrowhead Pharmaceuticals Close to a Cure for HBV?
Is Arrowhead Pharmaceuticals Close to a Cure for HBV?
Motley Fool
Arrowhead Pharmaceuticals
hepatitis B
Flag link:
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis
Pharmaceutical Business Review
Arrowhead Pharmaceuticals
clinical trials
cystic fibrosis
ARO-ENaC
RNAi
Flag link:

Pages